UCB Expands Bimzelx Indications with Three New FDA Approvals for Chronic Inflammatory Diseases

Three New Indications:
Bimzelx (bimekizumab-bkzx) has received FDA approval for the treatment of adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS).

First Dual Inhibitor:
Bimzelx is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for these indications, offering a new treatment option for chronic inflammatory diseases.

Clinical Benefits:
Clinical studies have shown that Bimzelx provides statistically significant improvements in signs and symptoms at Week 16, which were sustained to Week 52, across biologic-naïve and TNF inhibitor-inadequate responder populations.

Dosage and Administration:
The FDA recommended dosage of Bimzelx is 160 mg by subcutaneous injection every four weeks for adult patients with active PsA, active nr-axSpA with objective signs of inflammation, and active AS.

Availability:
Bimzelx is currently available for eligible patients, expanding treatment options for those living with chronic inflammatory diseases.